Arthritis and rheumatism
-
Arthritis and rheumatism · Sep 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). ⋯ In patients with active LN, overall renal response rates with ocrelizumab were numerically but not statistically significantly superior to those with placebo. Ocrelizumab treatment was associated with a higher rate of serious infections in the subgroup receiving background MMF.
-
Arthritis and rheumatism · Sep 2013
Randomized Controlled Trial Clinical TrialClinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
To evaluate the reasons that complete remission is not achieved or maintained with original treatment in some patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with rituximab (RTX) or with cyclophosphamide/azathioprine (CYC/AZA). ⋯ Current treatment regimens are largely successful in controlling AAV, but in approximately one-fourth of patients, active disease persists or recurs in the first 6 months despite treatment. PR3-ANCA positivity is a risk factor for recurrence or persistence of severe disease. ANCA titers and B cell detectability are poor predictors of both disease relapse and disease quiescence in the first 6 months.
-
Arthritis and rheumatism · Sep 2013
The circadian clock in murine chondrocytes regulates genes controlling key aspects of cartilage homeostasis.
To characterize the circadian clock in murine cartilage tissue and identify tissue-specific clock target genes, and to investigate whether the circadian clock changes during aging or during cartilage degeneration using an experimental mouse model of osteoarthritis (OA). ⋯ These results reveal an autonomous circadian clock in chondrocytes that can be implicated in key aspects of cartilage biology and pathology. Consequently, circadian disruption (e.g., during aging) may compromise tissue homeostasis and increase susceptibility to joint damage or disease.
-
Arthritis and rheumatism · Sep 2013
Editorial CommentOsteoarthritis: when chondrocytes don't wake up on time.
-
Arthritis and rheumatism · Aug 2013
Sphingosine 1-phosphate counteracts the effects of interleukin-1β in human chondrocytes.
The lipid mediator sphingosine 1-phosphate (S1P) is found in the synovial fluid of osteoarthritis (OA) patients. S1P protects bovine cartilage by counteracting the effects of interleukin-1β (IL-1β). This study was undertaken to examine the interaction of S1P and IL-1β in human OA chondrocytes. ⋯ In human chondrocytes, S1P reduces the induction of catabolic genes in the presence of IL-1β. Activation of the S1P2 receptor counteracts the detrimental phosphorylation of p38 MAPK by IL-1β.